Breast cancer prognosis signature: linking risk stratification to disease subtypes

Author:

Yu Fulong1,Quan Fei1,Xu Jinyuan1,Zhang Yan1,Xie Yi1,Zhang Jingyu1,Lan Yujia1,Yuan Huating1,Zhang Hongyi1,Cheng Shujun12,Xiao Yun1,Li Xia1

Affiliation:

1. College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150081, China

2. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100021, China

Abstract

AbstractBreast cancer is a very complex and heterogeneous disease with variable molecular mechanisms of carcinogenesis and clinical behaviors. The identification of prognostic risk factors may enable effective diagnosis and treatment of breast cancer. In particular, numerous gene-expression-based prognostic signatures were developed and some of them have already been applied into clinical trials and practice. In this study, we summarized several representative gene-expression-based signatures with significant prognostic value and separately assessed their ability of prognosis prediction in their originally targeted populations of breast cancer. Notably, many of the collected signatures were originally designed to predict the outcomes of estrogen receptor positive (ER+) patients or the whole breast cancer cohort; there are no typical signatures used for the prognostic prediction in a specific population of patients with the intrinsic subtype. We thus attempted to identify subtype-specific prognostic signatures via a computational framework for analyzing multi-omics profiles and patient survival. For both the discovery and an independent data set, we confirmed that subtype-specific signature is a strong and significant independent prognostic factor in the corresponding cohort. These results indicate that the subtype-specific prognostic signature has a much higher resolution in the risk stratification, which may lead to improved therapies and precision medicine for patients with breast cancer.

Funder

National Program on Key Basic Research Project

National High Technology Research and Development Program of China

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Harbin Medical University

Heilongjiang Province

Heilongjiang Postdoctoral Foundation

Funds for the Graduate Innovation Fund of Heilongjiang Province

Harbin Special Funds for Innovative Talents of Science and Technology Research Project

Publisher

Oxford University Press (OUP)

Subject

Molecular Biology,Information Systems

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3